Affinage

TRIM2

Tripartite motif-containing protein 2 · UniProt Q9C040

Length
744 aa
Mass
81.5 kDa
Annotated
2026-06-10
36 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TRIM2 is a RING-type E3 ubiquitin ligase that uses UbcH5a as its cognate E2 and functions prominently in neurons, where it binds and ubiquitinates neurofilament light chain (NF-L) to control axonal NF-L levels, neuronal polarity, and axon specification (PMID:18687884, PMID:20796172); loss of TRIM2 in mice and in humans with biallelic loss-of-function mutations causes early-onset axonal neuropathy with neurofilament accumulation (PMID:18687884, PMID:23562820). Its catalytic competence depends on RING-domain self-association, which a placental-mammal-specific divergence has abolished in the paralog TRIM3, restorable by heterodimerization with TRIM2 through their filamin and coiled-coil domains (PMID:36481767). Beyond NF-L, TRIM2 directs ubiquitin-dependent degradation of multiple pro-apoptotic and signaling substrates: it ubiquitinates Bim selectively when Bim is phosphorylated by p42/p44 MAPK, coupling survival signaling to apoptotic control in neuroprotection and tamoxifen-resistant breast cancer (PMID:21478148, PMID:28902352); it mediates K48-linked ubiquitination of BNIP3 at K130 to protect against ischemia-reperfusion injury (PMID:40883557); it promotes p53 ubiquitination and degradation (PMID:35672760, PMID:41391676); it drives K29/K48-linked degradation of the aldosterone synthase CYP11B2 (PMID:39725733); and it ubiquitinates the endolysosomal protein TMEM106B at cytosolic N-terminal lysines, with substrate recognition mediated by the tripartite motif beyond the RING and by a zinc-coordination motif in TMEM106B that controls lysosomal size (PMID:41484378). TRIM2 also possesses a RING-independent antiviral activity that restricts New World arenavirus entry and interacts with SIRPA to limit phagocytosis of apoptotic cells (PMID:30726215), and it engages the ESCRT component ALIX to regulate neural progenitor survival (PMID:32698497). Non-degradative or non-canonical activities have also been described, including stabilization of CPT1A to support fatty acid oxidation (PMID:38949993).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2008 High

    Established TRIM2 as a bona fide E3 ubiquitin ligase and identified NF-L as its substrate, defining a molecular basis for axonal maintenance.

    Evidence in vitro ubiquitination with UbcH5a, NF-L co-IP, and TRIM2-knockout mice with axonopathy

    PMID:18687884

    Open questions at the time
    • Ubiquitin linkage type on NF-L not defined
    • Whether NF-L degradation is proteasomal not directly shown
  2. 2010 Medium

    Connected TRIM2-mediated NF-L ubiquitination to the cell-biological decision of axon specification and neuronal polarity.

    Evidence RNAi knockdown and overexpression in cultured hippocampal neurons with morphological scoring

    PMID:20796172

    Open questions at the time
    • Single lab
    • Mechanism linking NF-L turnover to polarity not resolved
  3. 2011 High

    Identified Bim as a phosphorylation-gated TRIM2 substrate, coupling MAPK survival signaling to apoptotic regulation in neuroprotection.

    Evidence MS substrate ID with phospho-Bim bait, immunodepletion ubiquitination, phosphomutant analysis, neuronal shRNA

    PMID:21478148

    Open questions at the time
    • Ubiquitin linkage on Bim not characterized
    • Structural basis of phospho-dependent recognition unknown
  4. 2013 Medium

    Demonstrated that TRIM2 loss causes a human Mendelian axonal neuropathy, validating the mouse model in patients.

    Evidence whole-exome sequencing, patient fibroblast protein analysis, sural nerve biopsy

    PMID:23562820

    Open questions at the time
    • Single study
    • Genotype-phenotype range not established
  5. 2017 Medium

    Extended the TRIM2-Bim axis to cancer, showing GPER/MAPK-driven TRIM2 expression degrades Bim to confer tamoxifen resistance.

    Evidence Co-IP, pathway inhibitor dissection, and Bim manipulation in MCF-7/MCF-7R cells

    PMID:28902352

    Open questions at the time
    • Single lab
    • Direct ubiquitination in this context not shown
  6. 2019 High

    Revealed a RING-independent function: TRIM2 restricts New World arenavirus entry and interacts with SIRPA to limit phagocytosis, separating its antiviral role from ligase activity.

    Evidence Trim2-KO mice and patient fibroblasts, RING-domain mutants, interactome, phagocytosis assays

    PMID:30726215

    Open questions at the time
    • Molecular mechanism of viral entry restriction unresolved
    • Whether SIRPA is a ubiquitination substrate unknown
  7. 2020 Medium

    Linked TRIM2 to ESCRT machinery via ALIX in neural progenitor survival during neurogenesis.

    Evidence GST-Trim2 pulldown with LC-MS/MS in Xenopus and morpholino phenotyping

    PMID:32698497

    Open questions at the time
    • Single lab and model organism
    • Whether ALIX is a substrate or partner not resolved
  8. 2020 Low

    Reported an unusual deubiquitinating/stabilizing effect of TRIM2 on Snail1 promoting EMT in lung adenocarcinoma.

    Evidence Co-IP, Western blot, and ubiquitination assay in lung cancer cell lines

    PMID:32536816

    Open questions at the time
    • Deubiquitination claim for a RING E3 is mechanistically unusual and not validated by orthogonal methods
    • No reciprocal validation
  9. 2020 Medium

    Genetic allele comparison suggested the axonopathy phenotype may not require full ligase activity, complicating the catalytic model.

    Evidence CRISPR Trim2-null versus partial RING-deletion mouse strains with neuropathology

    PMID:32205255

    Open questions at the time
    • Residual ligase activity in deletion allele not quantified mechanistically
    • Single lab
  10. 2022 High

    Structurally explained TRIM2 RING-dimerization dependence and showed TRIM2 can restore the inactive paralog TRIM3 via heterodimerization.

    Evidence RING domain structure-function, mutagenesis, in vitro E3 assays, cellular Co-IP

    PMID:36481767

    Open questions at the time
    • Functional consequences of TRIM2-TRIM3 heterodimers in vivo not defined
  11. 2022 Medium

    Placed TRIM2 in a stress-signaling axis where CEBPB drives TRIM2 expression to degrade p53 in colorectal cancer.

    Evidence ChIP for CEBPB-promoter binding, Co-IP, ubiquitination assay, RNA-seq

    PMID:35672760

    Open questions at the time
    • Ubiquitin linkage on p53 not defined
    • Single lab
  12. 2024 Medium

    Identified a non-degradative metabolic role: TRIM2 binds and enhances CPT1A activity to support fatty acid oxidation and survival under glutamine deprivation.

    Evidence Co-IP, CPT1A activity and lipid assays, xenograft growth, ATF4 induction

    PMID:38949993

    Open questions at the time
    • Mechanism of enzymatic enhancement unknown
    • Whether ubiquitination is involved unresolved
  13. 2024 Medium

    Defined TRIM2 control of aldosterone synthesis via K29/K48-linked degradation of CYP11B2.

    Evidence siRNA E3 screen, Co-IP, linkage-specific ubiquitination, aldosterone measurement in adrenal tumor cells

    PMID:39725733

    Open questions at the time
    • Single lab
    • Physiological regulation of this axis not established
  14. 2024 Medium

    Demonstrated a context-specific vascular role for TRIM2 in inflammation-driven angiogenesis through HIF-1α and eNOS signaling.

    Evidence Trim2-/- mice in two models, endothelial shRNA, HIF-1α fractionation, eNOS phosphorylation

    PMID:38542330

    Open questions at the time
    • Direct substrate in endothelial cells not identified
    • Single lab
  15. 2025 High

    Resolved a precise degron, identifying K48-linked ubiquitination of BNIP3 at K130 as a protective axis in intestinal ischemia-reperfusion.

    Evidence Co-IP, K130R mutagenesis, K48-linkage ubiquitination assay, KO mouse, hypoxia/reoxygenation death assay

    PMID:40883557

    Open questions at the time
    • Whether this axis operates in non-intestinal tissues unknown
  16. 2025 Medium

    Connected TRIM2 to m6A regulation (YTHDF3) and reaffirmed p53 as a degradation substrate in uveal melanoma.

    Evidence RIP-qPCR for m6A, Co-IP, cycloheximide chase

    PMID:41391676

    Open questions at the time
    • Ubiquitin linkage on p53 not specified
    • Single lab
  17. 2026 High

    Used unbiased proximity labeling to place TRIM2 in the endolysosomal pathway, identifying TMEM106B as a substrate and defining tripartite-motif-mediated, structure-based substrate recognition.

    Evidence ubiquitin-specific proximity labeling, biochemical pulldown, structural studies, TMEM106B lysine mutagenesis, lysosomal size assays

    PMID:41484378

    Open questions at the time
    • Linkage type on TMEM106B not detailed
    • Physiological role in lysosomal regulation in vivo not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how TRIM2 selects among its diverse substrates across neurons, immune cells, endothelium, and tumors, and how its RING-dependent ligase activity, RING-independent antiviral function, and non-degradative metabolic roles are coordinated within a single protein.
  • No unifying model of substrate selection
  • Tissue-specific cofactors unknown
  • Relationship between catalytic and non-catalytic functions undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 5 GO:0140096 catalytic activity, acting on a protein 4 GO:0016874 ligase activity 3 GO:0031386 protein tag activity 2
Localization
GO:0005829 cytosol 2 GO:0005764 lysosome 1
Pathway
R-HSA-392499 Metabolism of proteins 5 R-HSA-5357801 Programmed Cell Death 2 R-HSA-168256 Immune System 1
Partners
BCL2L11BNIP3CPT1ACYP11B2NEFLSIRPATMEM106BTP53

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 TRIM2 is an UbcH5a-dependent E3 ubiquitin ligase that binds to neurofilament light subunit (NF-L) and regulates NF-L ubiquitination; mice deficient in TRIM2 accumulate NF-L in axons leading to axonopathy and neurodegeneration. In vitro ubiquitination assay with UbcH5a, co-immunoprecipitation of TRIM2 with NF-L, TRIM2 knockout mouse model with histopathological analysis Proceedings of the National Academy of Sciences of the United States of America High 18687884
2010 TRIM2 regulates axon specification in hippocampal neurons by ubiquitinating NF-L; RNAi knockdown abolishes neuronal polarity (no axon formed) while overexpression induces multiple axons. RNA interference knockdown and overexpression in cultured mouse hippocampal neurons with morphological analysis; mechanistic link via NF-L ubiquitination Journal of neurochemistry Medium 20796172
2011 TRIM2 is the E3 ubiquitin ligase that ubiquitinates the pro-apoptotic protein Bim; TRIM2 binds Bim only when Bim is phosphorylated by p42/p44 MAPK (does not interact with nonphosphorylatable 3ABim mutant), and TRIM2 immunodepletion reduces Bim ubiquitination; TRIM2 suppression stabilizes Bim and blocks neuroprotection in rapid ischemic tolerance. Proteomics/mass spectrometry substrate identification using phospho-GST-Bim as bait, co-immunoprecipitation, immunodepletion assay, lentiviral shRNAmir knockdown in neurons, phosphomutant Bim analysis The Journal of biological chemistry High 21478148
2013 Loss-of-function compound heterozygous mutations in TRIM2 cause early-onset axonal neuropathy in humans, with absence of TRIM2 protein leading to axonal accumulation of neurofilaments, consistent with the mouse Trim2 gene-trap model. Whole-exome sequencing, mRNA/protein stability analysis in patient fibroblasts, sural nerve biopsy histopathology, comparison with Trim2 gene-trap mouse model Human molecular genetics Medium 23562820
2017 TRIM2 acts downstream of GPER-activated MAPK/ERK signaling to ubiquitinate and degrade Bim, contributing to tamoxifen resistance in ER+ breast cancer cells; MAPK/ERK (not PI3K/AKT) activation increases TRIM2 levels and enhances TRIM2–Bim binding. Co-immunoprecipitation, Western blot, Bim overexpression/knockdown in MCF-7 and MCF-7R cells, pathway inhibitor studies International journal of oncology Medium 28902352
2019 TRIM2 restricts New World arenavirus (Junín, Tacaribe) entry into cells; this antiviral activity is independent of the RING domain (ubiquitin ligase activity). TRIM2 interacts with SIRPA (signal regulatory protein α), a known inhibitor of phagocytosis, and TRIM2 limits phagocytosis of apoptotic cells. Trim2-knockout mice and patient fibroblasts challenged with NWA, TRIM2 RING-domain mutant constructs, interactome analysis identifying SIRPA, phagocytosis assays PLoS biology High 30726215
2020 TRIM2 interacts with and deubiquitinates/stabilizes Snail1 protein in lung adenocarcinoma cells, reducing Snail1 ubiquitination-dependent degradation and promoting EMT, proliferation, and invasion. Co-immunoprecipitation, Western blot, ubiquitination assay, TRIM2 overexpression and knockdown in lung adenocarcinoma cell lines Cancer cell international Low 32536816
2020 In Xenopus, TRIM2 interacts with ALIX (ALG-2 interacting protein X) of the ESCRT complex; trim2 morphant embryos show clustering and apoptosis of neural progenitors phenocopying Alix KO, suggesting TRIM2–ALIX interaction regulates neural progenitor survival during neurogenesis. GST-Trim2 pulldown from Xenopus embryonic lysates with LC-MS/MS identification of ALIX, co-expression analysis, morpholino knockdown with phenotypic characterization Cells Medium 32698497
2020 Trim2-null (CRISPR-Cas9) mice develop axonal neuropathy with NF-L accumulation in axons; a separate partial RING-domain deletion strain (Trim2C/C) with reduced ubiquitination activity does not recapitulate this neuropathy, suggesting the axonopathy may not require full ubiquitin ligase activity. CRISPR-Cas9 knockout mice, histopathology of multiple neuronal populations, comparison of two Trim2 mutant alleles with different domain deletions Neurobiology of disease Medium 32205255
2022 The RING domain of human TRIM3 (TRIM2 paralog) is monomeric and inactive due to placental mammal-specific amino acid changes that prevent self-association but not E2 recognition; TRIM3 activity is restored by substituting the relevant region with TRIM2 sequence or by heterodimerization with TRIM2. TRIM2 and TRIM3 interact in cells via their filamin and coiled-coil domains, respectively. Crystal structure / structure-function analysis of RING domains, mutagenesis, in vitro E3 ligase assays, cellular co-immunoprecipitation Nature communications High 36481767
2022 TRIM2 promotes p53 ubiquitination and degradation in colorectal cancer cells; CEBPB acts as an upstream transcription factor that binds the TRIM2 promoter and drives its expression in response to epinephrine, linking stress signaling to p53 stability. Chromatin immunoprecipitation (ChIP) for CEBPB binding to TRIM2 promoter, co-immunoprecipitation of TRIM2 with p53, ubiquitination assay, transcriptome sequencing Journal of translational medicine Medium 35672760
2024 TRIM2 specifically interacts with CPT1A (carnitine O-palmitoyltransferase 1, the rate-limiting enzyme of fatty acid oxidation) and enhances its enzymatic activity, thereby regulating intracellular lipid levels and protecting cancer cells from glutamine deprivation-induced apoptosis; TRIM2 expression in this context is induced by ATF4. Co-immunoprecipitation of TRIM2 with CPT1A, CPT1A enzymatic activity assay, lipid level measurement, TRIM2 knockdown/overexpression with apoptosis and proliferation assays, xenograft tumor growth The FEBS journal Medium 38949993
2024 TRIM2 interacts with CYP11B2 (aldosterone synthase) via its RBCC domain and promotes K29/K48-linked polyubiquitination and proteasomal degradation of CYP11B2, thereby reducing aldosterone production in adrenal tumor cells. siRNA E3 ligase screen, co-immunoprecipitation of TRIM2 with CYP11B2, ubiquitination assay specifying K29/K48 linkages, overexpression assays in adrenal tumor cells measuring aldosterone levels Cellular and molecular life sciences : CMLS Medium 39725733
2024 TRIM2 knockdown in endothelial cells attenuates inflammation-driven (but not hypoxia-driven) angiogenesis by reducing nuclear HIF-1α accumulation and downstream eNOS phosphorylation; Trim2-/- mice show reduced adventitial neovascularization in an inflammation model but not in hindlimb ischemia. CRISPR/Cas9 Trim2-/- mice in periarterial collar and hindlimb ischemia models, lentiviral shRNA knockdown in endothelial cells, HIF-1α nuclear fractionation, eNOS phosphorylation Western blot International journal of molecular sciences Medium 38542330
2025 TRIM2 directly interacts with the pro-apoptotic protein BNIP3 and mediates K48-linked polyubiquitination of BNIP3 at lysine 130 (K130), targeting it for proteasomal degradation; mutation K130R abolishes TRIM2-mediated ubiquitination, stabilizes BNIP3, and increases cell death; this TRIM2–BNIP3 axis protects against intestinal ischemia-reperfusion injury. Co-immunoprecipitation of TRIM2 with BNIP3, site-directed mutagenesis (K130R), ubiquitination assay specifying K48 linkage, TRIM2 genetic deletion mouse model, hypoxia/reoxygenation cell death assay Communications biology High 40883557
2026 Using ubiquitin-specific proximity labeling in cells, TRIM2 was found to target proteins of the endolysosomal pathway; specifically, TRIM2 ubiquitinates TMEM106B at lysine residues in its cytosolic N-terminal region. Substrate recognition involves a direct interaction between TRIM2 and a zinc-coordination motif in TMEM106B that mediates homodimerization and is required for lysosomal size regulation. The tripartite motif of TRIM2 (beyond the RING) contributes to substrate recruitment. Ubiquitin-specific proximity labeling (UbID), biochemical pulldown, structural studies, site-directed mutagenesis of TMEM106B lysine residues, lysosomal size assays EMBO reports High 41484378
2025 TRIM2 knockdown and overexpression in primary neurons regulate NF-L protein levels and α-synuclein aggregation, suggesting TRIM2 modulates both substrates relevant to Parkinson's disease neuropathology. Lentiviral knockdown and overexpression in primary neurons, measurement of NF-L levels and α-synuclein aggregation; peripheral proteomic analysis showing increased plasma/CSF NF-L in TRIM2 SNP carriers bioRxivpreprint Low bio_10.1101_2025.02.21.25322301
2025 TRIM2 is an m6A-modified substrate of YTHDF3; TRIM2 interacts with and ubiquitinates p53, promoting its degradation via the ubiquitin-proteasome system in uveal melanoma cells. RIP-qPCR confirming m6A modification of TRIM2 by YTHDF3, co-immunoprecipitation of TRIM2 with p53, cycloheximide chase assay demonstrating TRIM2-mediated p53 degradation Cellular signalling Medium 41391676
2014 Crystallization of the C-terminal NHL domain of human TRIM2 (residues 465–744) yielded crystals diffracting to 1.7 Å resolution (space group P21), enabling structural characterization of this substrate-recognition domain. Recombinant protein expression/purification, X-ray crystallography, molecular replacement phasing Acta crystallographica. Section F, Structural biology communications Low 24817735

Source papers

Stage 0 corpus · 36 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 123 18687884
2013 Deficiency of the E3 ubiquitin ligase TRIM2 in early-onset axonal neuropathy. Human molecular genetics 61 23562820
2022 Stress-induced epinephrine promotes epithelial-to-mesenchymal transition and stemness of CRC through the CEBPB/TRIM2/P53 axis. Journal of translational medicine 56 35672760
2017 GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis. International journal of oncology 54 28902352
2011 Identification of a novel Bcl-2-interacting mediator of cell death (Bim) E3 ligase, tripartite motif-containing protein 2 (TRIM2), and its role in rapid ischemic tolerance-induced neuroprotection. The Journal of biological chemistry 51 21478148
2015 MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer. Gynecologic oncology 42 26472353
2010 The E3-ubiquitin ligase TRIM2 regulates neuronal polarization. Journal of neurochemistry 39 20796172
2020 Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Oncogene 35 32929153
2020 TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma. Cancer cell international 28 32536816
2018 TRIM2 regulates the development and metastasis of tumorous cells of osteosarcoma. International journal of oncology 27 30066883
2021 MicroRNA-145-5p targeting of TRIM2 mediates the apoptosis of retinal ganglion cells via the PI3K/AKT signaling pathway in glaucoma. The journal of gene medicine 25 34291866
2019 TRIM2, a novel member of the antiviral family, limits New World arenavirus entry. PLoS biology 25 30726215
2021 Knockdown of long non‑coding RNA DLEU2 suppresses idiopathic pulmonary fibrosis by regulating the microRNA‑369‑3p/TRIM2 axis. International journal of molecular medicine 23 33760118
2023 Genome-scale CRISPR screen identifies TRIM2 and SLC35A1 associated with porcine epidemic diarrhoea virus infection. International journal of biological macromolecules 22 37499712
2019 TRIM2 is a novel promoter of human colorectal cancer. Scandinavian journal of gastroenterology 21 30916596
2015 Exome sequencing reveals homozygous TRIM2 mutation in a patient with early onset CMT and bilateral vocal cord paralysis. Human genetics 21 25893792
2022 Expression and Role of TRIM2 in Human Diseases. BioMed research international 20 36051486
2022 Divergent self-association properties of paralogous proteins TRIM2 and TRIM3 regulate their E3 ligase activity. Nature communications 18 36481767
2020 A recessive Trim2 mutation causes an axonal neuropathy in mice. Neurobiology of disease 16 32205255
2020 Long non-coding RNA NR2F1-AS1 promoted neuroblastoma progression through miR-493-5p/TRIM2 axis. European review for medical and pharmacological sciences 16 33378023
2018 Exploring the Roles of CREBRF and TRIM2 in the Regulation of Angiogenesis by High-Density Lipoproteins. International journal of molecular sciences 16 29958463
2022 LINC01535 Attenuates ccRCC Progression through Regulation of the miR-146b-5p/TRIM2 Axis and Inactivation of the PI3K/Akt Pathway. Journal of oncology 10 35342411
2020 Interplay of TRIM2 E3 Ubiquitin Ligase and ALIX/ESCRT Complex: Control of Developmental Plasticity During Early Neurogenesis. Cells 10 32698497
2024 TRIM2 promotes metabolic adaptation to glutamine deprivation via enhancement of CPT1A activity. The FEBS journal 9 38949993
2020 Expanding the phenotypic spectrum of TRIM2-associated Charcot-Marie-Tooth disease. Journal of the peripheral nervous system : JPNS 6 32815244
2024 TRIM2 Selectively Regulates Inflammation-Driven Pathological Angiogenesis without Affecting Physiological Hypoxia-Mediated Angiogenesis. International journal of molecular sciences 4 38542330
2023 Hsa_circ_0001361 facilitates cell progression and glycolytic metabolism in neuroblastoma via interacting with mir-490-5p to induce TRIM2 upregulation. Metabolic brain disease 4 36920626
2024 CircORC2 promoted proliferation and inhibited the sensitivity of osteosarcoma cell lines to cisplatin by regulating the miR-485-3p/TRIM2 axis. Journal of cell communication and signaling 3 38946721
2014 Expression, purification, crystallization and preliminary X-ray diffraction analysis of the C-terminal NHL domain of human TRIM2. Acta crystallographica. Section F, Structural biology communications 2 24817735
2026 TRIM2 E3 ligase substrate discovery reveals zinc-mediated regulation of TMEM106B in the endolysosomal pathway. EMBO reports 1 41484378
2025 Curcumin suppresses colorectal cancer by inhibiting TRIM2 and mTOR signaling. Translational oncology 1 40946588
2024 E3 ubiquitin ligase TRIM2 identified as a novel suppressor of CYP11B2 and aldosterone production. Cellular and molecular life sciences : CMLS 1 39725733
2026 Integrated multi-omics analysis and functional validation reveal the role of TRIM2 as a potential novel biomarker in breast cancer. Breast cancer research : BCR 0 41918119
2025 TRIM2 inhibits apoptosis by ubiquitinating BNIP3 to protect the intestine against ischemia-reperfusion injury in mice. Communications biology 0 40883557
2025 YTHDF3-TRIM2-P53 axis promotes malignant progression in uveal melanoma (UVM). Cellular signalling 0 41391676
2025 TRIM2 exacerbates the advancement of idiopathic pulmonary fibrosis by modulating β-catenin and endoplasmic reticulum stress. European journal of medical research 0 41413621

Missed literature

Know a paper Affinage missed for TRIM2? Flag it for the maintainers and the community.

No submissions yet.